02335.HK
Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H
HKSE · Healthcare · Biotechnology · CN
HKD 28.56
+0.07%Aug 26, 2026, 19:01 UTC
Mackyo Pharmaceuticals announced the completion of Phase II clinical trials for its self-developed candidate drug MT200605, which treats acute ischemic stroke, demonstrating significant efficacy and good safety.
Source:Aug 17, 2026, 13:22 UTC
Micot Medical announced that research results for its main product XTL6001 were accepted for presentation at multiple top international academic conferences in diabetes, metabolic diseases, and kidney diseases, including EASD 2026 and ASN Kidney Week 2026.
Source: